Immunotherapy improves survival in kidney cancer patients with brain metastases
A recent real world study has found that giving immunotherapy [...]
NICE approves cabozantinib plus nivolumab for advanced kidney cancer
The National Institute for Health and Care Excellence (NICE) has approved the [...]
PRISM study highlights possibility of reducing dose of immunotherapy
The CheckMate-214 clinical trial was the first study to show [...]
World-class radiotherapy in the UK
Led by the All Party Parliamentary Group for Radiotherapy, the [...]
Summary of kidney cancer highlights from ASCO GU 2024
This year’s American Society of Clinical Oncology Genitourinary Cancers (ASCO [...]
Cancer treatment could identify patients most likely to respond to cancer drugs
Scientists from Cancer Research UK and Memorial Sloan Kettering Cancer [...]
Belzutifan and shows better quality of life compared to everolimus
People with kidney cancer have been shown to have changes [...]
Lenvatinib plus pembrolizumab for advanced kidney cancer
The final survival information from the phase 3 CLEAR study [...]
Patient’s perspective on pembrolizumab/lenvatinib for kidney cancer
In 2009, Cesar Fuentes was first diagnosed with kidney cancer [...]
METEOR study: Cabozantinib compared to everolimus in advanced kidney cancer
Cabozantinib is a tyrosine kinase inhibitor that is used [...]
